Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR-SEQUENCE
2024-510967-41-00Phase 3Authorised
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of panitumumab, bevacizumab, FOLFOX and FOLFIRI in colorectal cancer (CRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: 36-month progression-free survival rate (PFSR). Planned start Mar 2024; status: authorised.
02
Drugs
panitumumabbevacizumabFOLFOXFOLFIRI
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-510967-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510967-41-00.